Near Infrared Spectroscopy (NIRS) in Severe Sepsis

NCT ID: NCT00167596

Last Updated: 2016-07-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

103 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-07-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the usefulness of an optimization of muscle perfusion and oxygenation, as assessed by the NIRS technique, in critically ill patients with sepsis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The systemic inflammatory response to sepsis may cause impaired tissue oxygenation that can persist despite the restoration of a normal hemodynamic profile and systemic oxygen transport.

Therefore, the assessment of tissue oxygenation and perfusion is recommended in patients with severe sepsis.

The InSpectra tissue spectrometer relies on continuous wave near infrared (NIR) technology to estimate non invasively local tissue hemoglobin oxygen saturation in tissue (% StO2). This technology had been tested in a variety of systems: standard theoretical models of light transport, isolated blood, isolated blood-perfused animal organs and healthy human volunteers with induced limb ischemia. In critical-care medicine, NIRS has also been used to evaluate muscle oxygenation in trauma resuscitation and in lower extremity and abdominal compartment syndrome. However, NIRS has been rarely utilised to measure tissue blood flow and oxygen uptake in critically ill patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critical Illness Severe Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Early goal directed therapy based on StO2 evaluation

Group Type EXPERIMENTAL

Near Infrared Spectroscopy

Intervention Type DEVICE

resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid

2

Early goal directed therapy

Group Type ACTIVE_COMPARATOR

conventional

Intervention Type DEVICE

resuscitation will be based according to Surviving Sepsis Campaign

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Near Infrared Spectroscopy

resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid

Intervention Type DEVICE

conventional

resuscitation will be based according to Surviving Sepsis Campaign

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Two of four criteria for the systemic inflammatory response syndrome; and one of the following:

* systolic blood pressure =\< 90 mm Hg; or
* a blood lactate concentration =\> 4 mmol/l; or
* skin marbling; or
* impaired consciousness; or
* urine output \< 30 ml/h.

Exclusion Criteria

* Age \< 18 years
* Pregnancy
* Do-not-resuscitate status
* Advanced directives restricting implementation of the protocol
* Obesity (body mass index \[BMI\] \> 30)
* Anasarca
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hutchinson Technology Inc

INDUSTRY

Sponsor Role collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role collaborator

University of Versailles

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Djillali Annane

Professor in medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Djillali Annane, MD, PhD

Role: STUDY_CHAIR

Raymond Poincaré Hospital, AP-HP

Olivier Nardi, MD

Role: STUDY_DIRECTOR

Raymond Poincaré Hospital, AP-HP

Gwenhael Colin, MD

Role: PRINCIPAL_INVESTIGATOR

Raymond Poincaré Hospital, AP-HP

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Raymond Poincaré Hospital

Garches, , France

Site Status

Hôpital Nord AP HM

Marseille, , France

Site Status

CHU Tours

Tours, , France

Site Status

GERLACH Herwig

Berlin, , Germany

Site Status

University Hospital Rostock

Rostock, , Germany

Site Status

NANAS Serafeim

Athens, , Greece

Site Status

EZAVALA Elizabeth

Barcelona, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France Germany Greece Spain

References

Explore related publications, articles, or registry entries linked to this study.

Nardi O, Zavala E, Martin C, Nanas S, Scheeren T, Polito A, Borrat X, Annane D. Targeting skeletal muscle tissue oxygenation (StO2) in adults with severe sepsis and septic shock: a randomised controlled trial (OTO-StS Study). BMJ Open. 2018 Mar 19;8(3):e017581. doi: 10.1136/bmjopen-2017-017581.

Reference Type DERIVED
PMID: 29555789 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

05008

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.